REVIEW PAPER<BR>Anti-ribosomal P protein antibodies: clinical significance and role in pathogenesis of systemic lupus erythematosus

Marzena Olesińska

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2005
vol. 43

Send email

Copy url:

abstract:

REVIEW PAPER
Anti-ribosomal P protein antibodies: clinical significance and role in pathogenesis of systemic lupus erythematosus

Marzena Olesińska

Ru 2005, 43; 5: 274-279

Online publish date: 2005/10/27

View full text Get citation

Ribosomal P protein is a pentamere composed of 3 phosphoproteins: P0, P1 and P2 with molecular weights, respectively: 38, 19 i 17 kDa.
Their function is not exactly known, it is supposed that are essential for all 3 stages of protein synthesis and for regulation of ribosomal GTP activity.
Anti-P antibodies react to at least 1 epitope common to all 3 proteins and corresponding to a single sequential antigenic determinant present in the carboxyl-terminal 22-amino-acid sequence. ELISA and immunoblotting are used in detection of anti-P antibodies.
There is a wide variation in the reported prevalence of these antibodies in SLE patients. Some authors found it in 5-10% but the others revealed anti-P in 42% of SLE patients.
It has been reported that anti-ribosomal P antibodies correlate with high activity SLE, risk of CNS or renal involvement and hepatic or haematologic complications.

keywords:

anti-ribosomal P protein antibodies, systemic lupus erythematosus

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

REVIEW PAPERAnti-ribosomal P protein antibodies: clinical significance and role in pathogenesis of systemic lupus erythematosus

Marzena Olesińska

anti-ribosomal P protein antibodies, systemic lupus erythematosus

REVIEW PAPER
Anti-ribosomal P protein antibodies: clinical significance and role in pathogenesis of systemic lupus erythematosus